IL182353A0 - Methods using glycosaminoglycans for the treatment of kidney disease - Google Patents

Methods using glycosaminoglycans for the treatment of kidney disease

Info

Publication number
IL182353A0
IL182353A0 IL182353A IL18235307A IL182353A0 IL 182353 A0 IL182353 A0 IL 182353A0 IL 182353 A IL182353 A IL 182353A IL 18235307 A IL18235307 A IL 18235307A IL 182353 A0 IL182353 A0 IL 182353A0
Authority
IL
Israel
Prior art keywords
glycosaminoglycans
treatment
methods
kidney disease
kidney
Prior art date
Application number
IL182353A
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of IL182353A0 publication Critical patent/IL182353A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL182353A 2004-10-01 2007-04-01 Methods using glycosaminoglycans for the treatment of kidney disease IL182353A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61547204P 2004-10-01 2004-10-01
US62233204P 2004-10-26 2004-10-26
PCT/US2005/035790 WO2006039709A1 (en) 2004-10-01 2005-10-03 Methods using glycosaminoglycans for the treatment of kidney disease

Publications (1)

Publication Number Publication Date
IL182353A0 true IL182353A0 (en) 2008-04-13

Family

ID=36142893

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182353A IL182353A0 (en) 2004-10-01 2007-04-01 Methods using glycosaminoglycans for the treatment of kidney disease

Country Status (6)

Country Link
EP (1) EP1804810A4 (en)
JP (1) JP2008515807A (en)
AU (1) AU2005292202A1 (en)
CA (1) CA2583079A1 (en)
IL (1) IL182353A0 (en)
WO (1) WO2006039709A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616230A1 (en) * 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
WO2007125385A2 (en) 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
CA2851513A1 (en) * 2011-10-11 2013-04-18 Drp Biomedical, Inc. Method for treating acute kidney injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245907B (en) * 1991-05-17 1994-10-25 Alfa Wassermann Spa USE OF GLYCOSAMINOGLICANS IN THE TREATMENT OF DIABETIC NEPHROPATHY AND DIABETIC NEUROPATHY.
IT1270846B (en) * 1993-05-10 1997-05-13 Alfa Wassermann Spa USE OF SULODEXIDE AND MEDICINAL SPECIALTIES THAT CONTAIN IT IN THE TREATMENT OF DIABETIC NEPHROPATHY.
US20010005720A1 (en) * 1995-06-07 2001-06-28 U.S.A. As Represented By The Secretary Department Of Health And Human Services Method of treating chronic progressive vascular scarring diseases
US20030013680A1 (en) * 2001-06-12 2003-01-16 Keryx Methods using glycosaminoglycans for the treatment of nephropathy

Also Published As

Publication number Publication date
EP1804810A4 (en) 2008-02-27
EP1804810A1 (en) 2007-07-11
WO2006039709A1 (en) 2006-04-13
AU2005292202A1 (en) 2006-04-13
JP2008515807A (en) 2008-05-15
CA2583079A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
HK1248630A1 (en) System for combined ultrasound treatment
EP1928453A4 (en) Methods and compositions for the preventioin and treatment of kidney disease
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
IL181304A0 (en) Dihydropteridinones for the treatment of cancer diseases
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
EP1755670A4 (en) Methods for treating vascular disease
GB2430002B (en) Well treatment
EP1768656A4 (en) Treatment for ocular disease
IL182353A0 (en) Methods using glycosaminoglycans for the treatment of kidney disease
GB0400802D0 (en) Compounds for the treatment of disease
GB0426196D0 (en) Methods of treatment
GB0424085D0 (en) Well treatment
ZA200606780B (en) Compounds for the treatment of diseases
HUP0401379A3 (en) Process for the preparation of risperidon
GB0428291D0 (en) Methods of regenerating NOx-Absorbent
GB0516753D0 (en) Molecular methods for the treatment of disease
GB0415352D0 (en) Compounds for the treatment of disease
GB0425073D0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0425064D0 (en) Compounds useful for the treatment of diseases
AP2006003743A0 (en) Compounds useful for the treatment of diseases
GB0516619D0 (en) Methods of treatment of neoplastic disease